OptiNose — Q1 2018 Earnings Presentation
18 slides from OptiNose's earnings presentation, May 14, 2018
Slide 1: Building a Leading ENT / Allergy Specialty Company First Quarter 2018 Update
Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company First Quarter 2018 Update May 14, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Recent Key Accomplishments
Recent Key Accomplishments Retail Launch Aided Awareness April 2, 2018 87% within ENT / Allergy Specialty* Commercial 74% Lives Covered Total Trialists (61% Tier 3 Single Step or better)* 800 700 600 500 Encouraging 400 Submitted CS Physician Adoption 300 trial design to 200 in ENT / Allergy 100 FDA
Slide 4: Successful Launches Are Driven by Four Key Factors
Our Research on Over 300 Products Suggests Successful Launches are Driven by Four Key Factors Attractive Market…with High Unmet Need Importantly Differentiated Product Awareness / Execution Market Access 4
Slide 5: CRS is an Attractive Market…With High Unmet Need
CRS is an Attractive Market…With High Unmet Need 30 Million High Burden US Adults suffer from CRS Disease persists for many years and up to 10 million • of them have nasal • Significant quality of life impact polyps (comparable to CHF, COPD, Angina) 9.75 Million CRS patients seek Recognized Unmet Ne
Slide 6: Perceived Differentiation of XHANCE Translates into High Intention to Prescribe
Perceived Differentiation of XHANCE on Key Choice Drivers Translates into High Intention to Prescribe XHANCE is Perceived as Physician Stated Interest Differentiated on Key to Prescribe* Choice Drivers High Physician Interest in Prescribing is Reported After Presenting Product Profile (With Only Nas
Slide 7: Multi-Channel Integrated Marketing Program Increased Aided Awareness to 87%
Multi-Channel Integrated Marketing Program Increased Aided Awareness to 87% Awareness & Execution 87% . Digital and Non-Personal Awareness campaign 73% implemented 9/17/2017 65% . Clinical Nurse Educators deployed 11/18/2017 . Xhance Xperience program introduced in early March 28% . Approximately 80
Slide 8: XHANCE has Good Early Launch Market Access
XHANCE has Good Early Launch Market Access XHANCE Overall Access: April 2018 • Nationally, we believe 74% of commercial lives are in a plan where XHANCE is covered. 26% • We believe new drugs that launch at approval typically have 74% only 40% of commercial lives covered and 60% of commercial lives
Slide 9: XHANCE National Market Access
XHANCE National Market Access XHANCE Overall • We are focused on creating Access: April 2018 access for patients that minimizes hassle for prescribers and patients. 26% • XHANCE is on formulary for 65% 9% of commercial lives in a Tier 3 65% position requiring a previous trial of an INS or better. •
Slide 10: XHANCE Xperience Program - Initiated in Market on March 5th
XHANCE Xperience Program - Initiated in Market on March 5th XPERIENCE . Innovative launch program, planned for March through June, offering physicians and patients an opportunity to gain initial experience with XHANCE . Designed to facilitate accelerated trial and adoption, and to help address “prac
Slide 11: XHANCE Launch Accelerated by Xperience
XHANCE Launch Accelerated by Xperience Cumulative Cumulative Units Dispensed Physician Trialists 1,500 6,000 As of May 4, 29% of 1,351 5,203 called physicians have 5,000 1,200 prescribed XHANCE 4,000 900 3,000 600 2,000 Average of 2 calls to 300 convert physician 1,000 to a trialist 0 0 XPERIENCE 11
Slide 12: Encouraging Feedback From Xperience Program Survey
Encouraging Feedback From Xperience Program Survey Patient Responses Prior to Month 2 Refill (N=321) Patient Satisfaction 87% Experience Symptom 80% Improvement Prefer XHANCE 81% Recommend XHANCE 89% to a Friend Use without Difficulty 94% Note: in the same period that the 321 responses were received
Slide 13: Market Dynamics, Product Characteristics and Execution Provide a Strong Foundation
Market Dynamics, Product Characteristics and Execution to Date Provide a Strong Foundation for a Successful Launch Indicator/Objective Assessment Attractive Market…with High Unmet Need >80% Current Patients Dissatisfied with Existing Treatment >80% of patients frustrated with lack of symptom relief
Slide 14: Financial Review
Financial Review Q1 2018 Revenues and Q2 and Full Year 2018 Average Selling Price (ASP) Perspectives • A large majority of Q1 revenue is • As planned, we expect the Xperience related to inventory shipped in late- program to be the primary source of March to support retail pharmacy demand for XHANCE
Slide 15: Chronic Sinusitis Supplemental Indication (sNDA)
Chronic Sinusitis Supplemental Indication (sNDA) CS study design Selection of CRO First patients submitted to and study expected to FDA, meeting locations enroll in 4Q 2018 requested Chronic Sinusitis trial design expected to include co-primary endpoints: both an objective measure of inflammation an
Slide 16: 2018 Stands to be an Important Year
2018 Stands to be an Important Year Achieve greater than 87% aided awareness in target ENT and allergist audience during retail launch Secure market access for XHANCE ≥65% of patients with commercial insurance plans at retail launch, expanding to 75% by year end Key Objectives Successfully launch XH
Slide 17: Investor Relations
Investor Relations – NASDAQ: OPTN At 31 March 2018: 1 Analyst Coverage – $210 million in cash – 37.9 million common shares o/s BMO: Gary Nachman – 8.2 million options & warrants o/s – Long-term debt: $75 million Jefferies: David Steinberg Optinose Investor Contact Jonathan Neely, VP, Investor Relati
Slide 18: Building a Leading ENT / Allergy Specialty Company First Quarter 2018 Update
Building a Leading ENT / Allergy Specialty Company First Quarter 2018 Update May 14, 2018